Fate Therapeutics
FATE
74 hedge funds and large institutions have $101M invested in Fate Therapeutics in 2017 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 18 increasing their positions, 22 reducing their positions, and 5 closing their positions.
280% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 5
23% more funds holding
Funds holding: 60 → 74 (+14)
17% more capital invested
Capital invested by funds: $86.2M → $101M (+$14.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.93% less ownership
Funds ownership: 64.28% → 61.35% (-2.9%)
18% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 22
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$927K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$426K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$316K |
| 4 |
6CM
683 Capital Management
New York
|
+$308K |
| 5 |
Neuberger Berman Group
New York
|
+$283K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$2.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.28M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$1.27M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$933K |
| 5 |
Renaissance Technologies
New York
|
-$302K |
FATE Hedge Fund Activity: Q3 2017 in Review
74 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2017, worth a combined $101M — up 17% from $86.2M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new FATE positions and 5 closed out — a net gain of 14 holders — while 18 added to existing stakes and 22 trimmed.
The largest buyer was Endurant Capital Management, opening a new position worth an estimated $927K. The largest seller was Kingdon Capital Management, cutting an estimated $2.6M.
- 74 institutional investors held Fate Therapeutics (FATE) as of Q3 2017, up from 60 in Q2 2017.
- Funds reported $101M of Fate Therapeutics stock for Q3 2017, up 17% quarter-over-quarter.
- 19 funds opened new Fate Therapeutics positions in Q3 2017 and 5 closed out, a net change of +14 holders.
- The largest Fate Therapeutics buyer in Q3 2017 was Endurant Capital Management, an estimated $927K added.
- The largest Fate Therapeutics seller in Q3 2017 was Kingdon Capital Management, an estimated $2.6M sold.
Based on aggregated 13F filings for Q3 2017.